Aberrant DNA methylation and expression of SPDEF and FOXA2 in airway epithelium of patients with COPD by Song, J et al.
  
 University of Groningen
Aberrant DNA methylation and expression of SPDEF and FOXA2 in airway epithelium of
patients with COPD
Song, J; Heijink, I H; Kistemaker, L E M; Reinders-Luinge, M; Kooistra, W; Noordhoek, J A;





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2017
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Song, J., Heijink, I. H., Kistemaker, L. E. M., Reinders-Luinge, M., Kooistra, W., Noordhoek, J. A., ...
Hylkema, M. N. (2017). Aberrant DNA methylation and expression of SPDEF and FOXA2 in airway
epithelium of patients with COPD. Clinical Epigenetics, 9, [42]. https://doi.org/10.1186/s13148-017-0341-7
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
RESEARCH Open Access
Aberrant DNA methylation and expression
of SPDEF and FOXA2 in airway epithelium
of patients with COPD
J. Song1,2,3,4, I. H. Heijink1,2, L. E. M. Kistemaker2,5, M. Reinders-Luinge1, W. Kooistra1, J. A. Noordhoek1,2, R. Gosens2,5,
C. A. Brandsma1,2, W. Timens1,2, P. S. Hiemstra6, M. G. Rots1 and M. N. Hylkema1,2,7*
Abstract
Background: Goblet cell metaplasia, a common feature of chronic obstructive pulmonary disease (COPD), is associated
with mucus hypersecretion which contributes to the morbidity and mortality among patients. Transcription factors
SAM-pointed domain-containing Ets-like factor (SPDEF) and forkhead box protein A2 (FOXA2) regulate goblet cell
differentiation. This study aimed to (1) investigate DNA methylation and expression of SPDEF and FOXA2 during goblet
cell differentiation and (2) compare this in airway epithelial cells from patients with COPD and controls during mucociliary
differentiation.
Methods: To assess DNA methylation and expression of SPDEF and FOXA2 during goblet cell differentiation, primary
airway epithelial cells, isolated from trachea (non-COPD controls) and bronchial tissue (patients with COPD), were
differentiated by culture at the air-liquid interface (ALI) in the presence of cytokine interleukin (IL)-13 to promote goblet
cell differentiation.
Results: We found that SPDEF expression was induced during goblet cell differentiation, while FOXA2 expression was
decreased. Importantly, CpG number 8 in the SPDEF promoter was hypermethylated upon differentiation, whereas DNA
methylation of FOXA2 promoter was not changed. In the absence of IL-13, COPD-derived ALI-cultured cells displayed
higher SPDEF expression than control-derived ALI cultures, whereas no difference was found for FOXA2 expression. This
was accompanied with hypomethylation of CpG number 6 in the SPDEF promoter and also hypomethylation of CpG
numbers 10 and 11 in the FOXA2 promoter.
Conclusions: These findings suggest that aberrant DNA methylation of SPDEF and FOXA2 is one of the factors underlying
mucus hypersecretion in COPD, opening new avenues for epigenetic-based inhibition of mucus hypersecretion.
Keywords: SPDEF, FOXA2, DNA methylation, Mucus, COPD
Background
Chronic bronchitis, one of the clinical phenotypes of
chronic obstructive pulmonary disease (COPD), is charac-
terized by goblet cell metaplasia and excessive mucus
production and secretion, which contributes to the
morbidity and mortality of patients [1–3]. The tracheo-
bronchial epithelium of the human airways consists of
basal cells, ciliated cells, club (Clara) cells, goblet cells,
and neuroendocrine cells [4, 5]. Basal cells serve as the
progenitor cells from which goblet cells and ciliated cells
are derived, both in the normal airway epithelia renewal
process and during abnormal remodeling in disease [6, 7].
Goblet cell differentiation is dictated by a large network of
genes, in which transcription factors SAM-pointed domain-
containing ETS-like factor (SPDEF) and forkhead box pro-
tein A2 (FOXA2) are two key regulators. SPDEF is required
for goblet cell differentiation and mucus production, includ-
ing the major secreted airway mucin MUC5AC (mucin
5AC) [8–10], whereas FOXA2 is a potent inhibitor of goblet
cell differentiation in the lung [11–13]. Recent studies have
shown that SPDEF is expressed higher (messenger RNA
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(mRNA)) in the large airway epithelium of smokers com-
pared to non-smokers [14, 15] and also expressed higher
(protein) in lung tissue of patients with asthma and COPD
compared to healthy controls [16]. FOXA2 was shown to be
reduced (both mRNA and protein) and was negatively
correlated with MUC5AC in bronchial epithelium of
patients with asthma [17] and in nasal tissue of individuals
with chronic rhinosinusitis [18]. In addition, FOXA2 was
expressed lower (mRNA) in small airway epithelium of both
healthy smokers and COPD smokers compared to non-
smokers [19].
DNA methylation is an important mechanism in the
regulation of gene expression during adult stem cell re-
newal and differentiation, as is shown for the differenti-
ation of hematopoietic, epidermal, and intestinal stem
cells [20–23]. However, the role of DNA methylation in
airway basal cell differentiation has not been evaluated.
Other studies showed that aberrant DNA methylation was
associated with dysregulation of SPDEF and FOXA2 ex-
pression in lung cancer [24, 25], although DNA methyla-
tion regulation of SPDEF and FOXA2 expression has not
been assessed in lung tissue of patients with COPD.
In this study, we aimed to investigate the DNA methyla-
tion and expression of SPDEF and FOXA2 during goblet
cell differentiation and further identify whether DNA
methylation and expression of SPDEF and FOXA2 are
different in patients with COPD compared to control sub-
jects after in vitro airway epithelial cell differentiation. Ex-
pression of SPDEF target genes MUC5AC and anterior
gradient 2 (AGR2) and the ciliated cell related gene Fork-
head Box J1 (FOXJ1) were additionally assessed.
Methods
Culture of PBEC cells
Primary human bronchial epithelial cells (PBECs) were
obtained from bronchial tissue harvested from trans-
plant recipient lungs of 16 patients with GOLD (Global
Initiative for Chronic Obstructive Lung Disease) stage
IV COPD and residual tracheal and main stem bronchial
tissue from 17 transplant donors (non-COPD controls).
No information was available from the transplant do-
nors. Selection criteria for transplant donors are listed in
the Eurotransplant guidelines including the absence of
primary lung disease, such as asthma and COPD, and no
more than 20 pack years of smoking history. Character-
istics of patients with COPD and details on the experi-
mental design are shown in Table 1.
For the initial experiments, the third passage PBECs from
control subjects 1–6 and patients with COPD 1–5 (Table 1)
were cultured in bronchial epithelium growth medium
(BEGM, Lonza, Walkersville, MD, USA) until confluence
on fibronectin/collagen pre-coated transwell inserts (0.4-
Table 1 Characteristics of subjects and experimental design
Culture condition Age (years) Sex Smoking status Pack years FEV1%pred FEV1/FVC% N (RNA) N (DNA)
ALI with IL-13a COPD 1 56 M Ex 30 31 29 5 5
COPD 2 59 F Ex 41 87 59
COPD 3 60 F Ex 20 33 38
COPD 4 56 F Ex 30 14 25
COPD 5 61 F Ex 26 21 28
Non-COPD controls 1–6 NA NA NA NA NA NA 6 6
ALI without IL-13b COPD 6 58 F Ex 40 18 25 7 8
COPD 7 61 F Ex 35 20 25
COPD 8 55 F Ex 18 19 52
COPD 9 49 M Ex 11 20 22
COPD 10 60 M Ex 38 16 29
COPD 11 48 M Ex 25 12 23
COPD 12 58 F Ex 38 60 46
COPD 13 63 M Non 0 41 45
COPD 14 53 M Ex 30 25 25
COPD 15 57 M Ex 30 11 31
COPD 16 57 F Ex 45 23 24
Non-COPD controls 11–17 NA NA NA NA NA NA 7 7
Abbreviations: COPD chronic obstructive pulmonary disease, M male, F female, Ex ex-smoker, Non non-smoker, NA not available, FEV1%pred forced expiratory
volume during the first second as percentage of predicted, FEV1/FVC% the ratio of FEV1 to FVC (forced vital capacity), ALI air-liquid interface culture, IL-13
interleukin 13, N (RNA) number of RNA samples in total, N (DNA) number of DNA samples in total
aCells were cultured at ALI in the presence of IL-13 and harvested after 0, 14, 21 and 28 days
bCells were cultured at ALI without IL-13 and harvested after 14 days
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μm pore size, 12-mm diameter; Corning, NY, USA) and
were allowed to differentiate at air-liquid interface (ALI)
culture in the presence of interleukin (IL)-13 (1 ng/ml;
Peprotech, Rocky Hill, NJ, USA) to enhance goblet cell
differentiation (Fig. 1a) as previously described [26]. Cells
were harvested after 0, 14, 21, or 28 days of air exposure for
analysis of morphology, mRNA expression, and DNA
methylation. For the latter experiments, the third
passage PBECs from control subjects 7–17 and COPD
patients 6–16 (Table 1) were cultured in BEGM
medium until confluence on pre-coated transwell in-
serts (0.4-μm pore size, 6.5-mm diameter; Corning) and
allowed to differentiate at ALI culture without IL-13
(Fig. 4a) as described previously [27]. The cells were
harvested after 14 days of air exposure for analysis of
mRNA expression and DNA methylation.
For morphology analyses in transverse, the transwell
inserts were formalin-fixed and embedded in paraffin
according to Corning’s instructions, and cross sections
(5 μm thick) were analyzed after immunohistochemistry
staining. For morphology analyses in horizontal, trans-
well inserts were fixed with 4% (w/v) paraformaldehyde
(Merck, Darmstadt, Germany), after which the mem-
brane was cut into four quarters and analyzed after
immunohistochemistry staining.
Immunohistochemistry
Paraffin sections and insert membranes were investigated
for the presence of ciliated cells and goblet cells using
standard immunohistochemical procedures. Ciliated cells
were determined by staining slides with a monoclonal







Fig. 1 Characterization of the differentiation state of primary bronchial epithelial cells (PBEC) cultured in the air-liquid interface (ALI) model. a
Schematic representation of the ALI culture model. PBECs were seeded on to a transwell insert and grown until confluence. Thereafter, apical
medium was removed to create an ALI. Cells were harvested after 0, 14, 21, or 28 days for RNA, DNA, and morphology analysis. b–d PBEC from
control subjects 1–6 (Table 1, n = 6) were cultured at ALI with IL-13 stimulation. b Representative images of immunohistochemistry staining on
the differentiated ciliated cells and goblet cells at ALI day 21. Ciliated cells were determined by acetylated-α-tubulin antibody staining and
specified by arrows in the images; goblet cells were determined by Alcian Blue staining and MUC5AC antibody staining and were specified by
arrow heads in the images. mRNA expressions of c MUC5AC, d AGR2, e SPDEF, and f FOXA2 were analyzed by real-time quantitative PCR at four
different time points. Medians are indicated. Significance was tested by the Kruskal-Wallis non-parametric test with Dunn’s posttest data. ns not
significant. *p < 0.05; **p < 0.01. Data from days 14, 21, and 28 were compared to day 0
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T7451, St. Louis, MO, USA) and visualized with diamino-
benzidine (DAB, Sigma) solution. In the same sections,
goblet cells were subsequently visualized after staining
with Alcian Blue. MUC5AC-positive cells were deter-
mined with a monoclonal mouse anti-MUC5AC antibody
(Abcam, ab3649, Cambridge, UK) and visualized with 3-
amino-9-ethylcarbazole (AEC, Sigma).
mRNA expression by quantitative real-time PCR
Total RNA from PBEC was extracted using Trizol reagent
(Thermo Fisher Scientific, Carlshad, USA), according to the
manufacturer’s instructions. RNA quantity and purity were
assessed using NanoDrop 2000 (Thermo Scientific). Then,
500 ng of total RNA was used for complementary DNA
(cDNA) synthesis with random primers using Superscript
II RNase H - Reverse transcriptase (Thermo Fisher
Scientific). SPDEF, MUC5AC, AGR2, FOXA2, FOXJ1, and
GAPDH expression were quantified using 5 ng cDNA,
qPCRMasterMix Plus (Eurogentec, Belgium), and Taqman
gene-specific primer/probes (SPDEF: Hs01026050_m1; MU
C5AC: Hs00873651_Mh; AGR2: Hs00356521_m1; FOXA2:
Hs00232764_m1; FOXJ1: Hs00230964_m1; GAPDH: Hs0
2758991_g1, Thermo Fisher Scientific) for 40 cycles with
LightCycler® 480 Real-Time PCR System (Roche, Basel,
Switzerland). Data were analyzed with LightCycler® 480 SW
1.5 software (Roche) and the Fit point method, according
to the manufacturer’s instructions. Expression levels relative
to GAPDH were determined with the formula 2−ΔCp (Cp
means crossing points). Samples for which no amplification
could be detected were assigned a Cp value of 40 (the total
number of PCR cycles).
Methylation analysis by pyrosequencing
For DNA methylation analysis of the target regions,
genomic DNA was extracted with chloroform-isopropanol
and bisulfite converted using the EZ DNA Methylation-
Kit (Zymo Research), following the manufacturer’s proto-
col. Bisulfite-converted DNA (10–20 ng) was amplified by
PCR in a 25 μl reaction using the Pyromark PCR kit
(Qiagen). Pyrosequencing was performed on the Pyro-
mark Q24 pyrosequencer (Qiagen) according to the
manufacturer’s guidelines, using a specific sequencing
primer. Analysis of methylation levels at each CpG site
was determined using Pyromark Q24 Software (Qiagen).
The pyrosequencing primers’ information is presented in
Additional file 1: Table S1.
Statistics
Results obtained from qRT-PCR and pyrosequencing are
expressed as median and range, respectively. For compari-
sons between undifferentiated (day 0) and differentiated
epithelial cells (days 14, 21, and 28), the Kruskal-Wallis
non-parametric test with Dunn’s posttest was applied. For
comparisons of expression levels between COPD and
controls, the Mann-Whitney U test was applied. Correl-
ation analyses of the level of methylation level and mRNA
within the same sample was tested by Spearman non-
parametric correlation test. All statistical analyses were
performed with Prism v5.0.
Results
SPDEF and FOXA2 expression profiles during epithelial
cell differentiation in the presence of IL-13
First, in order to validate the role of transcription factors
SPDEF and FOXA2 in goblet cell differentiation, PBECs
from six control individuals (Table 1, control subjects 1–
6) were ALI cultured for 28 days in the presence of IL-13
to promote goblet cell differentiation (Fig. 1a). At days 0,
14, 21, and 28, the differentiation state of PBEC was char-
acterized by immunohistochemistry staining and quantita-
tive real-time PCR. As expected, this protocol induced the
differentiation of goblet cells as shown by the Alcian Blue-
positive cells and MUC5AC-positive cells after 14 to
28 days of ALI culture (Fig. 1b). Immunohistochemistry
staining demonstrated that approximately 5% of the cells
represented goblet cells, whereas the majority of cells con-
sisted of ciliated cells (tubulin positive) or other cells
(negative for both Alcian Blue and tubulin).
Goblet cell differentiation was accompanied by in-
creased expression of MUC5AC (59.6-fold) and Anterior
gradient 2 (AGR2) (4.5-fold), which encodes a potential
chaperone required for mucin packaging (Fig. 1c, d).
These changes were observed after 14 days of ALI culture
compared to expression at day 0, and the expression levels
remained consistent after 21 and 28 days of ALI culture
(Fig. 1c, d). As expected, increased MUC5AC expression
was accompanied by increased expression of transcription
factor SPDEF (2.8-fold at day 21, 2.2-fold at day 28) and
decreased expression of FOXA2 (to 28.6% of the start level
at day 21, to 19.7% at day 28) (Fig. 1e, f ). In line with the
differentiation of ciliated cells, increased expression of the
ciliated cell marker Forkhead Box J1 (FOXJ1, a key tran-
scription factor for ciliated cell differentiation) was also
found (Additional file 2: Figure S1).
DNA methylation dynamics within SPDEF and FOXA2
promoter during IL-13-induced goblet cell differentiation
Next, DNA methylation of SPDEF and FOXA2 was
assessed in the total cell population at different time
points during goblet cell differentiation (Table 1, control
subjects 1–6). As DNA methylation of CpG sites in the
region of the first exon and the promoter (including the
TSS) has been described to be tightly correlated with the
gene transcription [28], DNA methylation of CpG sites
in these specific regions were analyzed in the following
experiments. Fourteen CpG sites within the SPDEF pro-
moter and first exon were analyzed at five loci (Fig. 2a,
loci A to E) using pyrosequencing analysis. Compared to
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day 0 of ALI culture, methylation levels of CpG site
numbers 3 and 8 increased significantly at day 14 (CpG
number 3, from 88 to 93%; CpG number 8, from 16 to
27%) and the methylation level of CpG number 8
remained higher after 21 and 28 days of ALI culture
(Fig. 2b). Importantly, the methylation level in CpG
number 8 was positively correlated with mRNA expres-
sion of SPDEF (Spearman r = 0.567, p < 0.004, Additional
file 3: Figure S2). CpG number 15 was the only CpG site
of which methylation was decreased at day 28 of ALI
culture compared to day 0 (from very low level of 3% at
day 0 to 2% at day 28, Fig. 2b).
For FOXA2, six CpG sites that were part of a CpG is-
land in the promoter and first exon were examined
(Fig. 3a, CpG numbers 10–15). Methylation in these
sites did not change despite of the observed FOXA2
downregulation during differentiation (Fig. 3b).
In order to investigate goblet cell differentiation in
COPD, primary cells from five patients with COPD
(Table 1, COPD patients 1–5) were cultured at ALI in the
presence of IL-13 using the same protocol. Similar to the
observations in cells from controls, increased expression
of the goblet cell markers (MUC5AC, AGR2, and SPDEF)
and the ciliated cell marker (FOXJ1) were observed after
14 to 28 days of ALI culture (Additional file 4: Figure
S3a). In addition, a same trend of DNA methylation
dynamics in the SPDEF promoter was observed
(Additional file 5: Figure S4a) and the methylation level of
CpG number 8 was positively correlated with mRNA
expression of SPDEF (Spearman r = 0.6165, p < 0.004,
Additional file 5: Figure S4b). However, different from the
observations in control, FOXA2 expression did not
decreased during the IL-13-induced goblet cell differenti-






















































































































Fig. 2 Dynamic changes of DNA methylation in the SPDEF promoter during goblet cell differentiation of PBEC from control subjects. a Schematic
representation of the promoter region of the SPDEF gene, outlining the putative binding sites for the most relevant transcription factors (STAT6,
GFI, NKX2-1/NKX3-1, SMAD, and FOXA1/FOXA2) as analyzed using MatInspector software. The transcription start site was shown as +1. CpGs are
indicated as vertical bars. DNA methylation status of 15 CpGs was analyzed using pyrosequencing for the indicated areas. b PBEC from control
subjects1–6 (Table 1, n = 6) were cultured at ALI, and DNA methylation levels were analyzed at four different time points. Data represent the
connected median methylation levels (min to max) of different CpG sites at each time points, and differential methylated CpG sites are specified
with medians indicated. Significance was tested by the Kruskal-Wallis non-parametric test with Dunn’s posttest data. ns not significant. *p < 0.05;
**p < 0.01. Data from days 14, 21, and 28 were compared to day 0
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Figure S3b), whereas loss of DNA methylation in the
FOXA2 promoter was observed (CpG number 14, from
12% at day 0 to 8% at day 28; CpG number 15, from 15%
at day 0 to 11% at day 28, Additional file 6: Figure S5).
Aberrant expression and DNA methylation of SPDEF and
FOXA2 in promotor region airway epithelial cells of COPD
patients
In order to investigate putative differences in airway
epithelial cell differentiation between COPD and control,
PBECs from COPD and control subjects (Table 1, COPD
patients 6–16 and control subjects 7–17) were differenti-
ated at ALI culture in the absence of IL-13, and gene ex-
pression and DNA methylation levels were compared in
the total cell population after 14 days of ALI culture
(Fig. 4a). To exclude variables such as batch effects, cul-
tures and analyses were performed simultaneously using
the same reagents. We found that epithelial cells derived
from patients with COPD had significantly higher
mRNA expressions of MUC5AC, AGR2, and SPDEF
than epithelial cells from controls (MUC5AC, 21.1-fold;
SPDEF, 1.9-fold; AGR2, 2.9-fold, Fig. 4b), whereas no dif-
ference was found in FOXA2 and FOXJ1 expression be-
tween COPD-derived cells and control-derived cells
(Fig. 4b and Additional file 7: Figure S6).
COPD-derived cells presented significant lower methy-
lation levels of CpG site number 6 in the SPDEF pro-
moter (85% in control, 73% in COPD, Fig. 5a) and also
lower methylation levels of three CpG sites in the
FOXA2 promoter (CpG number 10: 4% in control and
2% in COPD, CpG number 11: 5% in control and 3% in
COPD, CpG number 15: 13% in control and 9% in
COPD, Fig. 5b) than control-derived cells at ALI day 14.
Discussion
In this study, we had two main observations. First, SPDEF
expression in epithelial cells was increased during IL-13-
induced goblet cell differentiation and correlated with al-
tered DNA methylation in epithelial cells, derived from
both controls and patients with COPD. Second, SPDEF
and MUC5AC were higher expressed in ALI-differentiated
epithelial cells from patients with COPD compared to
controls, which was accompanied with DNA hypomethy-
lation in the SPDEF promoter. Furthermore, FOXA2 ex-
pression was not affected during airway epithelial cell
differentiation in patients with COPD but was decreased
during differentiation in controls. This was not accompan-
ied by changes in DNA methylation.
SPDEF has been described, by us and others, to be up-
regulated in human bronchial epithelial cells in response
to IL-13 [26, 29, 30]. Our study confirms the increased
SPDEF expression after IL-13 stimulation, both in epi-
thelial cells from controls and patients with COPD. Dur-
ing this process, SPDEF upregulation was accompanied
by dynamic changes of methylation at several CpG sites
of the SPDEF promoter. Importantly, methylation of
CpG number 8 was consistently and positively correlated
to SPDEF expression in the IL-13-induced goblet cell
differentiation of cells from both controls and patients
with COPD. This is of interest as CpG number 8 locates
in a putative binding site for transcription factor NK2
homeobox 1 (NKX2-1). NKX2-1 is an airway epithelial-
FOXA2
FOXA2 ALI+IL-13 control





















Fig. 3 Dynamic changes of DNA methylation in the FOXA2 promoter during goblet cell differentiation of PBEC from control subjects. a Schematic
representations of the promoter region of the FOXA2 gene, outlining the putative binding sites for transcription factors (STAT6, GFI, NKX2-1/NKX3-1, CTCF,
SPDEF, and SP1) (MatInspector, top relevants). DNA methylation levels of six CpG sites in the promoter, which were part of a CpG island (indicated in the
figure), were examined for the indicated areas. b PBEC from control subjects 1–6 (Table 1, n= 6) were cultured at ALI and DNA methylation levels were
analyzed at four different time points. Data represent the connected median methylation levels (min to max) of different CpG sites at each time points
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specific transcription factor which has been found to in-
hibit SPDEF expression and prevent ovalbumin-induced
goblet cell differentiation and lung inflammation in
transgenic Nkx2-1 overexpressing mice [31]. Interest-
ingly, NKX2-1 was found to be methylation sensitive in
the regulation of its target gene surfactant protein B and
myosin-binding protein H [32, 33]. The hypermethyla-
tion of CpG number 8 in the SPDEF promoter might
prevent binding of NKX2-1, leading to increased tran-
scription of SPDEF during differentiation. We speculate
that NKX2-1 is a transcription inhibitor of SPDEF and
that DNA methylation impairs the NKX2-1 inhibitory
effect on the SPDEF promoter activity. For now, there is
no direct evidence showing that SPDEF is a target gene
of NKX2-1 except for their inverse role in goblet cell dif-
ferentiation and mucus production. It will be interesting
to further investigate the relation of NKX2-1 binding
and SPDEF promoter methylation (particularly CpG
number 8) to SPDEF promoter activity in the future.
SPDEF and MUC5AC have previously been shown to be
highly expressed in bronchial epithelium of patients with
COPD [16], which is in agreement with our findings, in
which increased expression of SPDEF, MUC5AC, and AGR2
was found in COPD-derived ALI cultures when compared
to controls. Moreover, our data demonstrate that there was
hypomethylation of CpG number 6 in the SPDEF promoter
in the COPD-derived ALI cultures, which is in line with the
over-expression and hypomethylation of SPDEF in lung can-
cer [24]. There are some confounding factors that may have
contributed to the difference we found between COPD and
non-COPD controls. Although no genetic background in-
formation of non-COPD controls or COPD cases were
available, there is no evidence showing that the reported
CpG sites include any underlying SNPs except CpG site
number 2 in the SPDEF promoter, which was excluded be-
cause of a known G/A SNP. Besides lack of information on
medication, no information exists on whether the controls
have been smoking. However, we do not assign our findings
to a possible current smoke effect in non-COPD controls as
Beane et al. have shown that expression of SPDEF and
MUC5AC was significantly higher, instead of lower, in
current smokers compared to former and never smokers
[14]. In addition, the location of sampling of the primary
cells from control and COPD was not exactly the same. Epi-
thelial cells from COPD were obtained from the large bron-
chus, whereas samples from transplant donor controls were
obtained from the trachea/main stem area. However, goblet
cell density is decreased from proximal to distal airways [34,
35], and distal airways have been shown to be less prone for
goblet cell metaplasia by diminished expression of IL-13 sig-
naling components, including IL-13 receptor IL-13Rα1,
SPDEF, and FOXA3 [36]. These considerations support our
conclusion that patients with COPD have an increased ex-
pression of SPDEF and MUC5AC compared to controls and
suggest that our results might even be an underestimation.
As expected, FOXA2, a known repressor of goblet cell
differentiation [11, 13, 17, 29, 37] was reduced during IL-
13-induced epithelial cell differentiation. As FOXA2 is
negatively regulated by SPDEF [9, 38] and two putative











































































































































Fig. 4 Differential mRNA expression profiles in PBECs from COPD patients and control subjects. a Schematic representation of the ALI culture model.
PBECs from control 7–17 and COPD 6–16 (Table 1) were seeded onto transwell inserts and grown to confluence. Thereafter, apical medium was removed
to create an ALI. Cells were harvested after 14 days for RNA and DNA analysis. b Expressions of MUC5AC, AGR2, SPDEF, and FOXA2 were analyzed by
real-time quantitative PCR. Significance was tested by the Mann-Whitney U test. Medians are indicated. ns not significant. *p< 0.05; **p< 0.01
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exon of FOXA2, SPDEF may decrease FOXA2 expression
directly. FOXA2 is also regulated by promoter DNA methy-
lation. FOXA2 was shown to be repressed and hypermethy-
lated in its promoter in lung cancer [25], whereas it was
also shown that FOXA2 was activated with hypermethyla-
tion in the promoter during endoderm development [39].
In our study, we observed that FOXA2 was hypomethylated
in cells from patients with COPD after goblet cell differenti-
ation not only in the presence of IL-13 (CpG numbers 14
and 15) but also in the absence of IL-13 (CpG numbers 10,
11, and 15). In both cases, hypomethylation of FOXA2 was
not accompanied with a change in expression level. These
phenomena could be explained by the minor methylation
differences (around 2 to 4%), which might not result in any
biological effect on transcription, or a decreased binding of
repressive transcription factors/increased binding of active
transcription factors.
It is of note that FOXA2 is also essential for proper estab-
lishment of cellular junctions and maintenance of polarity
[40], whereas FOXA2, together with other apical junctional
complex-related genes, was shown to be decreased
(mRNA) in small airway epithelium of both healthy
smokers and COPD smokers compared to non-smokers
[19]. In agreement with previous findings, cultured bron-
chial epithelial cells from patients with COPD displayed ab-







































































































Fig. 5 Differential DNA methylation of SPDEF and FOXA2 in the PBECs from COPD patients and control subjects. PBECs from control 7–17 and
COPD 6–16 (Table 1) were differentiated at ALI for 14 days, and DNA methylation of a SPDEF and b FOXA2 was analyzed by pyrosequencing. Data
represent the connected median methylation levels (min to max) of different CpG sites in controls or in COPD, and differential methylated CpG
sites between COPD-derived cultures and control-derived cultures are shown. Significance was tested by the Mann-Whitney U test. Medians are
indicated. ns not significant. *p < 0.05; **p < 0.01
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junctions and regenerate a mucociliary epithelium [41],
which might be driven by aberrant DNA methylation pro-
files. It is therefore important to validate our finding and
further investigate the biological role of DNA methylation
in the FOXA2 promoter during airway epithelial cell differ-
entiation and also in COPD in the future.
We assessed DNA methylation in the total population
of differentiated cells, of which the goblet cell population
represents about 5%. Using pure cell populations of
basal cells, ciliated cells, club (Clara) cells, and goblet
cells in future studies will increase the opportunity to
find more differentiated methylation loci/regions. How-
ever, even using the total cell population, our approach
turned out to be sensitive enough to reveal difference
between COPD and controls, which may be indicative
for the magnitude of this methylation difference.
Conclusions
In summary, we have demonstrated that SPDEF expression
is increased during IL-13-induced goblet cell differentiation,
which correlates to hypermethylation of CpG number 8 in
the SPDEF promoter. SPDEF expression is also higher in
COPD-derived ALI cultures compared to control-derived
ALI cultures in the absence of IL-13, which is accompanied
with hypomethylation of CpG number 6 in the SPDEF pro-
moter. Moreover, FOXA2 is hypomethylated (CpG numbers
14 and 15) during IL-13-induced goblet cell differentiation
and also hypomethylated (CpG numbers 10 and 11) in
COPD without a change in expression level. This shows the
complex biology of airway epithelial cell differentiation
where different transcription factors are involved and ex-
pression and DNA methylation mutually affect each other.
Our study has shown the potential relevance of SPDEF
regarding mucus hypersecretion in COPD and the involve-
ment of altered methylation patterns in this phenomenon,
and these insights might prove useful for the future
development of epigenetic-based anti-mucus therapeutic
strategies [42].
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